Cargando…

FAP: Not Just a Biomarker but Druggable Target in Liver Fibrosis

Detalles Bibliográficos
Autores principales:	Kim, Jieun, Seki, Ekihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040959/ https://www.ncbi.nlm.nih.gov/pubmed/36681094 http://dx.doi.org/10.1016/j.jcmgh.2022.12.018

Ejemplares similares

Hyaluronan in liver fibrosis: basic mechanisms, clinical implications, and therapeutic targets
por: Kim, Jieun, et al.
Publicado: (2023)

Crossing the Rubicon: Adipose Tissue Autophagy Breaks Out NAFLD
por: Kim, Jieun, et al.
Publicado: (2021)

Acrolein, a New Villain in the Development of Alcoholic Liver Disease
por: Seki, Ekihiro
Publicado: (2016)

Nuclear Receptors: Opening Up New Avenues of Pediatric Fatty Liver Research
por: Pandyarajan, Vijay, et al.
Publicado: (2018)

Toll-Like Receptors in Liver Fibrosis: Cellular Crosstalk and Mechanisms
por: Yang, Ling, et al.
Publicado: (2012)

In Vivo and In Vitro Models to Study Liver Fibrosis: Mechanisms and Limitations
por: Lee, Young-Sun, et al.
Publicado: (2023)

Toll-Like Receptor Signaling and Liver Fibrosis
por: Aoyama, Tomonori, et al.
Publicado: (2010)

Basic and Clinical Advances in Chronic Liver Inflammation
por: Enomoto, Hirayuki, et al.
Publicado: (2016)

Intestinal Lipolysis Mitigates Nonalcoholic Fatty Liver Disease: New Roles for Carboxylesterase 2c in the Intestine
por: Pimienta, Michael, et al.
Publicado: (2019)

The Tumor Microenvironment: A Druggable Target for Metastatic Disease?
por: EBioMedicine
Publicado: (2018)

Toll-Like Receptor Signaling in Liver Diseases
por: Szabo, Gyongyi, et al.
Publicado: (2010)

Tumor Suppressor Down-Regulation Promotes Hepatocyte Proliferation: A New GANKster on the Block
por: Pimienta, Michael, et al.
Publicado: (2018)

Kupffer Cell TLR2/3 Signaling: A Pathway for EGCG Amelioration of Ethanol-Induced Hepatic Injury
por: Czech, Torrey Y., et al.
Publicado: (2019)

Novel Biomarkers and Druggable Targets in Advanced Melanoma
por: Ferrucci, Pier Francesco, et al.
Publicado: (2021)

Druggable Drivers of Lung Cancer
por: Fawdar, Shameem, et al.
Publicado: (2013)

TAK1-dependent autophagy: A suppressor of fatty liver disease and hepatic oncogenesis
por: Seki, Ekihiro
Publicado: (2014)

TAK1: A Molecular Link Between Liver Inflammation, Fibrosis, Steatosis, and Carcinogenesis
por: Wang, Weijun, et al.
Publicado: (2021)

A new mechanism of action of glucagon‐like peptide‐1 agonist in hepatic steatosis: Promotion of hepatic insulin clearance through induction of carcinoembryonic antigen‐related cell adhesion molecule 1
por: Czech, Torrey Y., et al.
Publicado: (2018)

VAV2: a novel prognostic marker and a druggable target for adrenocortical carcinoma
por: Ruggiero, Carmen, et al.
Publicado: (2017)

Esophageal Adenocarcinomas: A Need for Speed Driven by Immune Pathways That Have Druggable Targets
por: Souza, Rhonda F.
Publicado: (2018)

Origin of myofibroblasts in liver fibrosis
por: Brenner, David A, et al.
Publicado: (2012)

Dataset on FAP-induced emergence of spontaneous metastases and on the preparation of activatable FAP-targeting immunoliposomes to detect the metastases
por: Tansi, Felista L., et al.
Publicado: (2016)

Alcoholic liver disease: A current molecular and clinical perspective()
por: Ohashi, Koichiro, et al.
Publicado: (2018)

Radioligands Targeting Fibroblast Activation Protein (FAP)
por: Lindner, Thomas, et al.
Publicado: (2021)

MEOX1: a novel druggable target that orchestrates the activation of fibroblasts in cardiac fibrosis
por: Schumacher, David, et al.
Publicado: (2021)

Targeted Therapies and Druggable Genetic Anomalies in Acute Myeloid Leukemia: From Diagnostic Tools to Therapeutic Interventions
por: Lanza, Francesco, et al.
Publicado: (2021)

Non-invasive biomarkers of liver fibrosis in non-alcoholic fatty liver disease
por: Basheer, Maamon, et al.
Publicado: (2023)

The Druggable Pocketome of Corynebacterium diphtheriae: A New Approach for in silico Putative Druggable Targets
por: Hassan, Syed S., et al.
Publicado: (2018)

Tryptophan Metabolism as Source of New Prognostic Biomarkers for FAP Patients
por: Crotti, Sara, et al.
Publicado: (2019)

Beyond finding druggable targets and tumor mutational burden: to measure heterogeneity by ctDNA
por: Liu, Zhichao, et al.
Publicado: (2020)

Thyroid, Renal, and Breast Carcinomas, Chondrosarcoma, Colon Adenomas, and Ganglioneuroma: A New Cancer Syndrome, FAP, or Just Coincidence
por: Atta, Ihab Shafek, et al.
Publicado: (2016)

Druggable Targets of Squamous Cell Lung Cancer
por: Kim, Cheol Hyeon
Publicado: (2013)

Serum levels of angiotensin converting enzyme as a biomarker of liver fibrosis
por: Miranda, Aline Silva, et al.
Publicado: (2017)

From the Gut to the Liver: Another Organ to Watch in FAP Patients
por: Paulson, Spencer, et al.
Publicado: (2016)

The Role of Mitochondrial Dysfunction in Atrial Fibrillation: Translation to Druggable Target and Biomarker Discovery
por: Pool, Lisa, et al.
Publicado: (2021)

Is It Just?
Publicado: (1897)

Personalized medicine: exploiting druggable vulnerabilities for KRAS-driven lung cancer
por: Seguin, Laetitia, et al.
Publicado: (2018)

Mitochondrial Potassium Channels as Druggable Targets
por: Wrzosek, Antoni, et al.
Publicado: (2020)

Druggable genetic targets in endometrial cancer
por: Lehrer, Steven, et al.
Publicado: (2022)

Fibroblast activation protein (FAP) as a novel metabolic target
por: Sánchez-Garrido, Miguel Angel, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_bp3enhb61lde1463gv0av7d1oq